Lupus erythematosus and Sjögren's syndrome are not absolute contraindications for dental implants — but they require a significantly adapted protocol. Sjögren's syndrome is the more clinically demanding scenario: xerostomia reduces oral self-cleansing, increases peri-implantitis risk, and alters wound healing. Digital implant planning (CBCT, guided surgery, CAD/CAM surgical guides) is not optional for these patients — it is medically necessary, minimizing surgical trauma and enabling precise implant positions even with reduced bone density.
Systemic autoimmune diseases such as lupus erythematosus (SLE) and Sjögren's syndrome affect hundreds of thousands of people in Austria — with a marked predominance in women. Both conditions have direct effects on oral health and therefore on the prerequisites for implant treatment. While lupus primarily acts through immunosuppression and corticosteroid therapy, Sjögren's syndrome is characterized by an independent mechanism: the destruction of exocrine glands with consequent xerostomia.
This article explains which pathophysiological mechanisms are relevant for implant treatment, how the clinical protocol must be adapted, and what role digital dentistry — particularly 3D planning, guided surgery, and CAD/CAM prosthetics — plays in these patients.
Lupus Erythematosus (SLE): Immunosuppression as the Primary Implant Risk
In systemic lupus erythematosus (SLE), the greatest implant risk is not the underlying disease itself but the treatment. Standard therapy with hydroxychloroquine, corticosteroids (prednisolone), and immunosuppressants (azathioprine, mycophenolate mofetil, belimumab) directly interferes with the processes necessary for osseointegration.
Disease-specific factors also play a role: oral ulcerations (in ~40% of SLE patients), oral mucosal changes, and increased susceptibility to infection due to the dysregulated immune system. Active disease flares (SLEDAI ≥6) are an absolute contraindication for elective implant procedures.
| Factor | Clinical Relevance | Implant Consequence |
|---|---|---|
| Corticosteroids (≥7.5 mg/day) | Bone loss, delayed wound healing | Extended healing time, dose optimization before surgery |
| Hydroxychloroquine | No direct implant risk | No dose adjustment required |
| Mycophenolate mofetil | Increased infection risk | Extended perioperative antibiotic protocol |
| Active flare (SLEDAI ≥6) | Systemic inflammation, immune dysregulation | Absolute contraindication for elective procedures |
| Oral ulcerations | Disrupted mucosal integrity | Procedure only after complete healing |
| Antiphospholipid syndrome (APS) | Increased thrombosis risk | Anticoagulation management as for cardiac patients |
Sjögren's Syndrome: Xerostomia as an Independent Risk Factor for Osseointegration
Sjögren's syndrome is a chronic autoimmune disease in which the immune system attacks the exocrine glands — primarily the salivary and lacrimal glands. The resulting xerostomia (dry mouth) is not merely a comfort issue but has direct pathophysiological consequences for implant healing.
In the context of implant treatment, saliva fulfills several critical functions: it buffers pH, contains antimicrobial proteins (lysozyme, lactoferrin, IgA), promotes wound healing through growth factors (EGF, TGF-β), and protects the peri-implant mucosa from mechanical and microbial irritation. In xerostomia, all these functions are reduced or eliminated.
Without saliva, pH drops below 5.5 after meals — critical for peri-implant bone structure and the titanium oxide interface.
Salivary IgA and lysozyme are absent — anaerobic bacteria (Porphyromonas gingivalis, Treponema denticola) colonize peri-implant sulcular fluid more rapidly.
EGF (Epidermal Growth Factor) in saliva promotes epithelialization. In Sjögren's patients, EGF concentration is reduced by up to 60%.
Chronic xerostomia leads to atrophy of the oral mucosa — the peri-implant soft tissue cuff is thinner and more vulnerable to mechanical irritation.
Digital Diagnostics: Salivary Flow Analysis and CBCT Bone Quality Assessment
Before any implant planning in Sjögren's patients, a quantitative salivary flow analysis is mandatory. Unstimulated salivary flow (USF) is measured over 15 minutes — values below 0.1 ml/min indicate severe xerostomia and require intensive preparation (saliva substitutes, pilocarpine therapy, oral rinses) before the procedure.
In parallel, digital volume tomography (DVT/CBCT) provides not only implant planning but also precise bone quality assessment according to Misch (D1–D4). In Sjögren's patients, bone density is often reduced — partly due to concomitant corticosteroid therapy, partly due to the systemic inflammatory response. CBCT-based Hounsfield unit analysis enables precise assessment of whether immediate implantation or a two-stage protocol with bone augmentation is more appropriate.
Digital Treatment Protocol for Lupus and Sjögren's: 7 Steps
SLEDAI score (SLE) or ESSDAI score (Sjögren's) before treatment begins. Procedure only in stable disease (SLEDAI <4, ESSDAI <5). Coordination with treating rheumatologist regarding medication pause or adjustment.
Unstimulated salivary flow (USF) and stimulated salivary flow (SSF) measured over 15 minutes. If USF <0.1 ml/min: pilocarpine therapy (5 mg 3×/day) for 4–6 weeks before procedure. Saliva substitutes as permanent accompaniment.
3D volumetric tomography with Hounsfield unit analysis. Bone quality per Misch D1–D4. For D3/D4: planning with shorter, wider implants or bone augmentation. Digital implant planning (software: coDiagnostiX, Simplant) with safety margins to anatomical structures.
CAD/CAM-fabricated surgical guide from digital planning. Guided surgery reduces surgical trauma to a minimum — critical for patients with impaired wound healing. Minimally invasive incision design, flapless approach where anatomically possible.
Antibiotic prophylaxis: amoxicillin 2g 1h preoperatively (or clindamycin for penicillin allergy). Chlorhexidine rinse 0.2% for 4 weeks postoperatively. Saliva substitute application immediately postoperatively. Close wound monitoring: days 3, 7, 14.
Sjögren's syndrome with active xerostomia: 6–12 months healing time (vs. standard 3–6 months). SLE under corticosteroids: 4–8 months. Provisional restoration with removable temporary — no immediate loading. Regular stability measurement (Periotest, ISQ value).
Implant-supported restorations from CAD/CAM zirconia or PMMA — smooth surfaces reduce plaque accumulation in patients with reduced salivary flow. Recall interval: 3 months (vs. standard 6 months). Professional cleaning with Airflow technology. Home oral hygiene: electric toothbrush, interdental brushes, saliva substitute before sleep.
Implant Success Rates with Autoimmune Diseases: What the Evidence Shows
The evidence base for implant success rates in lupus and Sjögren's syndrome is more limited than for other risk groups (diabetes, osteoporosis) — but available studies show a differentiated picture.
| Condition | 5-Year Survival Rate | Main Complication | Protocol Adjustment |
|---|---|---|---|
| SLE (stable, under therapy) | 92–95% | Peri-implantitis (increased risk) | Extended antibiotic protocol, 3-month recall |
| SLE (active flare) | Contraindicated | Implant loss, wound healing disorder | Postpone until remission |
| Sjögren's (mild, USF >0.1 ml/min) | 90–94% | Increased plaque accumulation | 3-month recall, saliva substitutes |
| Sjögren's (severe, USF <0.1 ml/min) | 78–85% | Peri-implantitis, osseointegration failure | Pilocarpine pretreatment, 6–12 mo. healing |
| Sjögren's + corticosteroid therapy | 75–82% | Bone loss, infections | Combined protocol (corticosteroid + xerostomia) |
Why Digital Dentistry Is Particularly Relevant for Autoimmune Patients
In immunosuppressed or xerostomic patients, the margin for error in implant treatment is significantly smaller than in healthy patients. Any deviation from the optimal implant position — too superficial, too deep, wrong angulation — increases peri-implantitis risk and mechanical stress. Digital planning and guided surgery systematically reduce these sources of error.
CAD/CAM surgical guide from digital planning guarantees implant position with ±0.3 mm accuracy — critical with reduced bone density and impaired wound healing.
Hounsfield unit analysis identifies D3/D4 bone preoperatively. Protocol adjustment (implant diameter, length, primary stability) before the first incision is made.
Zirconia and PMMA restorations from the digital workflow have smoother surfaces than conventional metal-ceramic crowns — measurably reduces plaque accumulation in xerostomia patients.
Digital documentation of all measurements (ISQ, Periotest, probing depth) enables trend analysis over time — early signs of peri-implantitis are detected before they become clinically manifest.
Lupus and Sjögren's syndrome are not exclusion criteria for dental implants — but they require a significantly adapted protocol that goes beyond standard care. Sjögren's syndrome is the more clinically demanding scenario because xerostomia represents an independent risk factor, separate from immunosuppression. Digital implant planning — CBCT analysis, guided surgery, CAD/CAM prosthetics — is not optional for these patients but medically necessary: it minimizes surgical trauma, optimizes implant position, and reduces peri-implantitis susceptibility through more precise restoration geometries.
Related topic: Lupus and Sjögren's patients frequently receive corticosteroids as baseline therapy — with its own risk profile for implant healing. Article 25: Dental Implant and Corticosteroids/Immunosuppressants →
Related topic: Autoimmune patients with cardiovascular involvement (lupus carditis) have a combined risk profile. Article 31: Dental Implant with Heart Failure and Pacemaker →
Aftercare: Autoimmune patients require an intensified 3-month recall protocol. Article 22: Dental Implant Aftercare: The First 12 Months →
IIDZ Wien – Wissenschaftliche Redaktion
Wissenschaftliche Redaktion
Weitere Artikel
Thematisch verwandt
Hinweis: Diese Inhalte dienen ausschließlich der allgemeinen Information und ersetzen keine individuelle zahnärztliche Beratung. Das Institut für Implantologie und digitale Zahnmedizin Wien ist eine gemeinnützige, unabhängige Wissenschaftsplattform — kein Behandlungsbetrieb. Alle Angaben entsprechen dem aktuellen Stand der wissenschaftlichen Literatur; individuelle Behandlungsentscheidungen müssen stets mit einem approbierten Zahnarzt oder Facharzt getroffen werden.